Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of enpatoran in adults with active cutaneous manifestations of lupus erythematosus, with or without systemic disease, in this global, multicenter Phase 3 study. The study aims to assess enpatorans effect over 24 weeks compared to a placebo, focusing on skin disease activity and safety outcomes. Participants include those diagnosed with discoid, subacute cutaneous lupus, or active acute cutaneous lupus alongside systemic lupus erythematosus. Participants will receive either enpatoran tablets or matching placebo tablets orally twice daily for 24 weeks Day 1 to Day 168, alongside investigator-recommended standard of care. The study includes scheduled visits every 4 weeks, with a telehealth visit at Week 2. The intervention is administered as film-coated tablets, and the treatment period lasts for 24 weeks within an overall study duration of up to 35 weeks. During the study, participants will be monitored through regular visits every 4 weeks to assess skin disease using the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other clinical measurements. Researchers will evaluate skin improvement, lupus disease activity, adverse events, laboratory parameters, and corticosteroid use. Safety and treatment effects will be closely followed during and after the treatment period, with the primary outcome assessed at Week 24.
Actively Recruiting
Researchers are evaluating the efficacy of RO7837195 compared to a placebo in adults with moderately to severely active ulcerative colitis who have not responded well to conventional or advanced treatments. This Phase IIb study aims to assess how effective and safe RO7837195 is for these patients. The study is sponsored by Genentech, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants will undergo a screening period lasting up to 5 weeks to determine eligibility. The main treatment includes a 12-week placebo-controlled induction phase, after which all participants receive RO7837195 during a 40-week active treatment extension. RO7837195 is given according to predefined dose regimens, and the study includes multiple experimental groups receiving different doses, as well as a group initially receiving placebo followed by RO7837195. Throughout the study, participants will have regular assessments to measure clinical remission at week 12, clinical response, endoscopic improvement, and safety through monitoring adverse events and blood levels of the drug. The studys total duration includes the screening, treatment phases, and a safety follow-up after the last dose, with outcome measures tracked up to week 65. Researchers will also monitor for the development of antibodies against RO7837195 to further understand treatment effects and safety.
Actively Recruiting
Researchers are conducting an international clinical program to improve diagnosis, treatment, and understanding of childhood ependymoma in patients under 22 years old. The study aims to harmonize staging and care standards, assess biological markers, and develop treatment recommendations based on age, tumor location, and surgical outcomes. Patients are categorized into three groups based on residual disease and eligibility for radiotherapy to test different therapeutic strategies. The study includes three treatment strata Stratum 1 evaluates the impact of a 16-week chemotherapy regimen with VEC-CDDP after surgery and conformal radiotherapy in patients aged over 12 months to under 22 years with completely removed tumors. Stratum 2 examines the addition of high-dose methotrexate to VEC chemotherapy in patients with residual disease, followed by conformal radiotherapy and possibly an 8 Gy radiotherapy boost for inoperable residual tumors. Stratum 3 studies dose-dense chemotherapy with or without valproate in children under 12 months or those ineligible for radiotherapy. Patients not meeting these criteria enter an observational registry. Participants undergo centralized pathology and imaging reviews to confirm diagnosis and tumor resection status. Assessments include MRI scans, biological marker evaluations, and response to treatments. Researchers monitor progression-free survival, gross total resection rates, treatment response, neuropsychological and neuroendocrine effects, and safety over several years. The study involves scheduled visits, laboratory tests, and follow-up for up to five years to evaluate long-term outcomes.
Actively Recruiting
Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.
Actively Recruiting
Researchers are evaluating whether catheter-based endovascular left atrial appendage occlusion can reduce the risk of ischemic stroke or systemic embolism in people with atrial fibrillation who remain at high stroke risk despite ongoing oral anticoagulation treatment. This multicenter, open-label, randomized controlled trial with blinded assessment aims to clarify the benefit of this intervention for stroke prevention in this population. Participants are randomly assigned to receive either the WATCHMAN device for left atrial appendage occlusion or standard medical care without this procedure. The WATCHMAN device is placed via a catheter to close off the left atrial appendage. Participants continue their oral anticoagulation as prescribed. The study expects an average follow-up of about 4 years, with the primary analysis conducted after 265 stroke or embolism events have occurred. During the study, participants undergo regular monitoring and assessments to track the occurrence of ischemic stroke, systemic embolism, and other cardiovascular events. Cognitive function is also evaluated using the Montreal Cognitive Assessment. Safety and mortality outcomes will be recorded throughout the trial duration. Participants are followed for the full study period estimated at around 4 years to gather comprehensive data on the interventions effects.